Indian pharma companies are betting on Chinese partnerships to bring oral GLP-1 drugs to market, but the window to act is ...

GLP-1-A26-2 Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or ...

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech ...

Novo Nordisk A/S NVO reported positive topline results from its late-stage PIONEER TEENS trial, showing that oral semaglutide ...

Asia Pacific is expected to register the highest growth rate during the forecast period. The GLP-1 market, an incretin ...

Him & Hers announced Thursday that eligible users can now access the full r | Providers can now send prescriptions of Eli ...

Armed with new phase 3 data, Novo Nordisk has said it will file for approval of oral formulations of its GLP-1 agonist ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ...

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

Novo Nordisk (NVO) stock gains after oral semaglutide pill succeeds in pediatric type 2 diabetes trial. Company targets H2 ...

Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing number of effective approved obesity drugs. This practice raises practical questions.